Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma
10.3760/cma.j.cn371439-20200610-00022
- VernacularTitle:PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展
- Author:
Yan DING
;
Hongyan WANG
- From:
Journal of International Oncology
2021;48(2):113-116
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of the confirmed cases of esophageal cancer in Asia, and the degree of malignancy is high. There is a growing number of research on ESCC immunotherapy, particularly programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Among them, the most studied PD-1/PD-L1 inhibitors in ESCC are nivolumab, pembrolizumab, camrelizumab, toripalimab, tislelizumab, atozolizumab, SHR-1316 and durvalumab. Some of the clinical trials of these drugs are still in progress, and some have initially shown good results.
